Agency: Cordis | Branch: H2020 | Program: RIA | Phase: ICT-05-2014 | Award Amount: 3.96M | Year: 2015
At the 2011 OECD High-Level Meeting The Internet Economy: Generating Innovation and Growth, Vint Cerf, VP and Chief Internet Evangelist at Google, said that one of the biggest issues with the Internet is keeping the network as open as possible to invite as much innovation as we can with as little barrier to that innovation as possible, so that new Googles and Amazons and PayPals and Skypes can happen all around the world. A significant barrier to innovation by SMEs is the ossification of the Internet transport architecture. New groundbreaking services often require different transport protocols, better signalling between application and network, or a more flexible choice of links. A few large enterprises have the resources to support their innovations by developing their own transport systemsAdobe, Google and Microsoft have done so. Open sophisticated transport protocols exist now, but are difficult for SMEs to use owing to their lack of support across the Internet. NEAT addresses two obstacles to Internet innovation: 1) It lowers the barrier to service innovation by developing a free open-source transport system that will allow SMEs to leverage the rich set of available transport protocols. 2) It paves the way for an architectural change of the Internet where new transport layer services can seamlessly be integrated and quickly made available, minimising deployment difficulties, and allowing Internet innovators to take advantage of them wherever possible. By optionally signalling between applications and the network, NEAT demonstrates new avenues for in-network support of application services. By decoupling the services offered to applications from the underlying network technologies, NEAT enables seamless integration with different computing environments and generalised mobility. The NEAT transport system will provide built-in security and privacy, allowing the implementation of these functions more efficiently and making them more attractive to use.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: ICT-11-2014 | Award Amount: 6.54M | Year: 2015
There is a strong need for objective data about stability and performance of Mobile Broadband (MBB) networks, and for tools to rigorously and scientifically assess their performance. In particular, it is important to measure and understand the quality as experienced by the end user. Such information is very valuable for many parties including operators, regulators and policy makers, consumers and society at large, businesses whose services depend on MBB networks, researchers and innovators. MONROE proposes to design, build and operate an open, European-scale, and flexible platform with multi-homing capabilities to run experiments on operational 3G/4G Mobile Broadband networks. One of the main objectives of MONROE is to use the platform for the identification of key MBB performance parameters, thus enabling accurate, realistic and meaningful monitoring and assessment of the performance of MBB networks. MONROE also provides WIFI connectivity mimicking multi-homing in smartphones with both MBB and WiFi interfaces, to allow experimenting on different access technologies as well as explore new ways of combining them to increase performance and robustness. The users of the platform are in the core of the MONROE project. First, following the FIREs philosophy, MONROE offers a user-oriented closed-loop system design in which the experimental platform is open to external users, and where users are incorporated early on in the experimental design process. Second, MONROE will provide Experiments as a Service (EaaS), thus lowering the barrier for using the platform to external experimenters and users, by providing well-documented tools and adjustable, flexible, high-level scripts to execute experiments, collect results, and analyze data. Interoperability with existing FIRE and FP7 measurement platforms, jointly with the MONROEs effort to develop business and funding models, will guarantee sustainability and usefulness of the platform.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: ICT-06-2016 | Award Amount: 4.89M | Year: 2016
MELODIC will enable data-intensive applications to run within defined security, cost, and performance boundaries seamlessly on geographically distributed and federated cloud infrastructures. Serving the users needs and constraints, MELODIC will realise the potential of Cloud computing for big data and data-intensive applications by transparently taking advantage of distinct characteristics of available private and public clouds, dynamically optimise resource utilisation, consider data locality, conform to the users privacy needs and service requirements, and counter vendor lock-in. These benefits are achieved by integrating and extending the results and the open source platforms available from three major European Cloud projects with the Hadoop and Spark big data frameworks: The PaaSage platform will be used for intelligent and autonomic cross-cloud deployment and is extended with data aware modelling and deployment configuration reasoning; the CACTOS platform is extended with support for Hadoop and Spark in cross-Cloud application deployment and management; and the PaaSword platform will ensure unified data security and cross-Cloud privacy. MELODIC will integrate with the existing open source development teams for these platforms and the contributions will be released back to the used platforms as open source. The integrated MELODIC platform will be maintained and exploited by a professional software house, and tested in several demanding real world applications: scalable Customer Relationship Management, real-time optimised traffic routing, and fast and scalable processing of genomic data.
Agency: Cordis | Branch: FP7 | Program: JTI-CP-ARTEMIS | Phase: SP1-JTI-ARTEMIS-2013-AIPP5 | Award Amount: 93.92M | Year: 2014
Embedded systems are the key innovation driver to improve almost all mechatronic products with cheaper and even new functionalities. Furthermore, they strongly support todays information society as inter-system communication enabler. Consequently boundaries of application domains are alleviated and ad-hoc connections and interoperability play an increasing role. At the same time, multi-core and many-core computing platforms are becoming available on the market and provide a breakthrough for system (and application) integration. A major industrial challenge arises facing (cost) efficient integration of different applications with different levels of safety and security on a single computing platform in an open context. The objective of the EMC project (Embedded multi-core systems for mixed criticality applications in dynamic and changeable real-time environments) is to foster these changes through an innovative and sustainable service-oriented architecture approach for mixed criticality applications in dynamic and changeable real-time environments. The EMC2 project focuses on the industrialization of European research outcomes and builds on the results of previous ARTEMIS, European and National projects. It provides the paradigm shift to a new and sustainable system architecture which is suitable to handle open dynamic systems. EMC is part of the European Embedded Systems industry strategy to maintain its leading edge position by providing solutions for: . Dynamic Adaptability in Open Systems . Utilization of expensive system features only as Service-on-Demand in order to reduce the overall system cost. . Handling of mixed criticality applications under real-time conditions . Scalability and utmost flexibility . Full scale deployment and management of integrated tool chains, through the entire lifecycle Approved by ARTEMIS-JU on 12/12/2013 for EoN. Minor mistakes and typos corrected by the Coordinator, finally approved by ARTEMIS-JU on 24/01/2014. Amendment 1 changes approved by ECSEL-JU on 31/03/2015.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: NMBP-10-2016 | Award Amount: 6.09M | Year: 2017
The incidence of Cardiovascular Disease (CD) claims worldwide 17.1 million lives a year, with an estimated 31% of all deaths globally and a EU cost of 139 billion euros. Up to 40% of all deaths occur among the elderly. In spite of all medical efforts, the 5-year mortality was reduced significantly less than that of malignant diseases. This highlights the urgent need to overcome the difficulties associated with present pharmacological therapies (i.e. drug instability, and unspecific targeting) by developing new ground-breaking therapeutic strategies that go far beyond any current regimens. New approaches for safe, efficient, and heart-specific delivery of therapeutics are strongly required. CUPIDO is envisioned to meet these critical needs by providing an unconventional and effective strategy based on nanoparticle-assisted delivery of clinically available and novel therapeutics to the diseased heart. In particular, CUPIDO will develop innovative bioinspired hybrid nanoparticles formulated as biologicals delivery, which are i) biocompatible and biodegradable, ii) designed for crossing biological barriers, and iii) guidable to the heart. A combination of multidisciplinary manufacturing and validation approaches will be employed, bringing the envisioned product beyond the currently available clinical and day-to-day management of CD individuals. Scale-up production, and respect of medical regulatory requirements will allow CUPIDO to deliver a final product for future late pre-clinical and clinical studies. Altogether, CUPIDO will foster the translation of nanomedical applications toward the cardiac field, which although still in its start, offers great potential to overcome the limitations associated to the currently pharmacological treatments.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: EINFRA-9-2015 | Award Amount: 7.64M | Year: 2015
OpenDreamKit will deliver a flexible toolkit enabling research groups to set up Virtual Research Environments, customised to meet the varied needs of research projects in pure mathematics and applications and supporting the full research life-cycle from exploration, through proof and publication, to archival and sharing of data and code. OpenDreamKit will be built out of a sustainable ecosystem of community-developed open software, databases, and services, including popular tools such as LinBox, MPIR, Sage(sagemath.org), GAP, PariGP, LMFDB, and Singular. We will extend the Jupyter Notebook environment to provide a flexible UI. By improving and unifying existing building blocks, OpenDreamKit will maximise both sustainability and impact, with beneficiaries extending to scientific computing, physics, chemistry, biology and more and including researchers, teachers, and industrial practitioners. We will define a novel component-based VRE architecture and the adapt existing mathematical software, databases, and UI components to work well within it on varied platforms. Interfaces to standard HPC and grid services will be built in. Our architecture will be informed by recent research into the sociology of mathematical collaboration, so as to properly support actual research practice. The ease of set up, adaptability and global impact will be demonstrated in a variety of demonstrator VREs. We will ourselves study the social challenges associated with large-scale open source code development and of publications based on executable documents, to ensure sustainability. OpenDreamKit will be conducted by a Europe-wide demand-steered collaboration, including leading mathematicians, computational researchers, and software developers long track record of delivering innovative open source software solutions for their respective communities. All produced code and tools will be open source.
Agency: Cordis | Branch: H2020 | Program: IA | Phase: ICT-21-2016 | Award Amount: 1.29M | Year: 2016
Modern film production relies heavily on digital acquisition and transformation. Blending real-world cinematography and computer graphics necessitates a tight integration between the shooting set and post-production. Today, editing and color grading are more and more frequently initiated directly on set to enable interactions between the shooting crew and the creative team. To facilitate communication between live-action production and digital post-production, a new discipline has emerged, collectively known as on-set data acquisition. There is also an obvious need for efficient tools to check consistency of the data recorded, especially since the number of supporting capture devices and the ways of exploiting them is growing quickly. For visual effects (VFX), one of the most important aspects is the acquisition of dense and accurate 3D data from real-world sets and locations. Capturing specific data on set for VFX is a delicate balance between the requirements of VFX facilities and the practical realities of tight shooting schedules and limited budgets. To smooth the collaboration between all teams on set, LADIO delivers a new platform that will be tested incrementally on real productions during the project. LADIO extends 3D acquisition of the set and centralizes management of all data recorded during the shooting session. It relies on soft- and hardware connectors to capture devices, including new affordable 360 cameras and LiDARs, and interacts with production tools both on set and off set. The LADIO application proposes an original approach to monitor all data, metadata and production information. It keeps track of the temporal and spatial location of all the data. LADIOs decentralised data management and API rely on open standards, and its 3D reconstruction software will be released as open source. This is a game-changer for European SMEs who will achieve higher quality and more cost-effective VFX, based on a new streamlined production dataflow.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: BIOTEC-2-2015 | Award Amount: 10.71M | Year: 2016
Recent developments in omics technologies demand implementation of systems biology approaches to facilitate analysis and interpretation of the generated complex datasets.This is essential for biotechnological as well as preclinical and clinical applications. In comparison to previous approaches, most cancer relevant studies are confined to pattern recognition or at best modelling of single pathways, rather than the complex pathways and cross-talk determining cancer progression and drug response. Systematic tools that evaluate and validate personalised medicine approaches on a preclinical level are missing; an important prerequisite for translation into clinical practice. The overall objective of CanPathPro is to build and validate a new biotechnological application: a combined experimental and systems biology platform, which will be utilized in testing cancer signaling hypotheses in biomedical research and life sciences. Thus, the proposed project will focus on developing and refining bioinformatic and experimental tools for the evaluation of systems biology modelling predictions. Components comprise a highly controlled mouse experimental system, NGS, a quantitative proteomics based read-out of changes in pathway signalling and an integrative systems biology model for data integration. Testable hypotheses about biological systems will be generated and experimentally validated. The developed system tools will be made available to researchers, SMEs and industry for practical applications. Following this project, a commercial platform for interpretation and analysis of complex omics data and for deriving and testing new hypotheses will be set up by the participating companies and academic partners. CanPathPro will enhance the competitive potential of the SMEs involved expanding in the field of biotechnology, personalised medicine and drug development and also provide new opportunities for other SMEs working in the field of bioinformatics and biomedical applications.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: ICT-12-2015 | Award Amount: 2.90M | Year: 2016
Recent revelations about large-scale pervasive surveillance of Internet traffic have led to a rapidly expanding deployment of encryption in order to protect end-user privacy. At the same time, network operators and access providers rely on increasing use of in-network functionality provided by middleboxes and network function virtualization (NFV) approaches to improve network operations and management, and to provide additional value for their customers. In addition, new applications such as interactive video make new demands on the transport layer, requiring the deployment of new protocols and extensions, the deployment of which is impaired by the proliferation of middleboxes that cause them to fail. These three trends are on a collision course. The MAMI project seeks to restore balance among end-user privacy concerns in the face of pervasive surveillance, innovation in network protocols in the face of increasing ossification, and the provision of in-network functionality in a cooperative way. We aim to do this through the development and experimental deployment of a middlebox cooperation protocol (MCP) embedded in a more flexible transport layer, to be used together with ubiquitously deployed encryption. To ensure the applicability of the protocol, we will develop it on a background of middlebox behaviour models, derived from large-scale measurements of middleboxes in the public Internet conducted on top of a FIRE\ testbed. We will then evaluate the fitness of our proposed MCP to purpose by evaluating its applicability to a set of real-world use cases for transport layer evolution, focusing on incremental deployability in the presence of both cooperative and uncooperative middleboxes by experimentation in the Internet utilising the facilities provided by FIRE\ testbeds.
Agency: Cordis | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2015-ETN | Award Amount: 4.10M | Year: 2015
The AFib-TrainNet consortium will enable promising young scientists to become excellent research leaders of the future, capable of fighting the challenges that Atrial Fibrillation (AF) presents to the European population. AF is the most common sustained cardiac arrhythmia, occurring in between 1-2% of the general population. More than 6 million Europeans suffer from this arrhythmia and its prevalence is expected to increase by more than two-fold during the next 40 years due to increased life expectancy. Thus, AF is said to assume epidemic proportions. Current options for pharmacological therapy are limited by both low efficacy and side effects, including lifethreatening ventricular arrhythmias and severe extra-cardiac toxicities. A very limited number of novel AF drug therapies have been introduced in the last 20 years. This imbalance reflects a gap in understanding in both how AF develops and how it can be treated, which thereby limits the development of new medicines. Our ambition with the AFib-TrainNet is to fill this gap by producing new knowledge, leading to critical insight into origins and mechanisms of sustenance of atrial fibrillation. We will accomplish this by developing novel experimental and computational models recapitulating human AF, and employing these models on two very promising atrial biological targets. Experimental models will be instrumental in improving the understanding AFs underlying mechanisms, and will, along with clinical data, inform state-of-the-art computational models of human atrial electrophysiology. These new tools will permit fresh insight into the molecular, cellular and electrical mechanisms involved in the progression of healthy atria into an AF state. Our endeavor will deliver results which can be leveraged by the pharmaceutical industry to target AF drug development, and the work accomplished in AFib-TrainNet will thus constitute a beacon in the search for new AF medicine.